All News

Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.

Loqtorzi improved progression-free and overall survival versus chemotherapy in HER2-expressing advanced urothelial cancer.

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer.

Adding Truqap to Zytiga, prednisone, and ADT extended radiographic progression-free survival by 7.5 months in PTEN-deficient prostate cancer.

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.

Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC

Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.

Adjuvant Opdivo significantly extended relapse-free survival in patients with resected stage advanced melanoma.

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

Among patients with solid tumors, baseline emotional functioning was moderate, with lower functioning for female and younger patients.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

In patients with ER-positive, HER2-negative advanced breast cancer, giredestrant and Afinitor reduced risk of disease progression or death.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Adding Kisqali to a nonsteroidal aromatase inhibitor continued to reduce recurrence risk and improve survival at five years in early breast cancer.

Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.

Lenvima and Keytruda with chemo did not help patients with metastatic esophageal squamous cell carcinoma live longer than Keytruda and chemotherapy alone.

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

Home-based supervised physical activity has no major impact on fatigue and quality of life for patients with metastatic cancer receiving oral targeted therapy.